FLGT / Fulgent Genetics: Attractive Valuation, But I Prefer To Hold For Now

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsie more_horizontal

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares more_horizontal

Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT' more_horizontal

Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches. more_horizontal

We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its more_horizontal

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year. more_horizontal

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares more_horizontal

Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year. more_horizontal